Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma
Recruiting
- Conditions
- cancer in the gulletoesophageal cancer10017991
- Registration Number
- NL-OMON47705
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
(1) Histological confirmation of adenocarcinoma of the oesophagus
(2) Patients that will receive standard chemoradiation treatment before surgery for oesophageal carcinoma
(3) Ability to give informed consent
(4) Age 18 years or older
(5) no prior therapy for oesophageal carcinoma
Exclusion Criteria
(1) pregnancy
(2) Inflammation of the gastro-intestinal tract
(3) Brain metastasis
(4) Diastolic/ systolic Hypertension (>90/>140 mmHg), not responding to treatment
(5) Arterial thromboembolism in medical history
(6) Surgery within the month prior to start of bevacizumab treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary parameter is the alteration of the VEGF expression on mRNA level in<br /><br>the tumour before and during the course of neoadjuvant chemoradiation. In<br /><br>addition, in the bevacizumab treated cohort, the primary parameter is the<br /><br>activity (phosphorylation) of the VEGF receptor (VEGFR) in the tumour tissue<br /><br>obtained with biopsy and the microvessel density of the resection material of<br /><br>the tumour. </p><br>
- Secondary Outcome Measures
Name Time Method